HOOKIPA Pharma to Present at SVB Leerink 9th Annual Global Healthcare Conference
February 18 2020 - 8:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that HOOKIPA’s management team will present and host
one-on-one meetings at the SVB Leerink 9th Annual Global Healthcare
Conference, taking place February 25 - 27, 2020 in New York:
- Presentation: Tuesday, February 25, 2020 at
10:00 a.m. ET, Lotte New York Palace, Room
Kennedy I
A live audio webcast of the presentation held at the SVB Leerink
Healthcare Conference will be available within the Investors &
Media section of HOOKIPA’s website at
https://ir.hookipapharma.com/events. An archived replay will be
accessible for 30 days following the event.
About
HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics, targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®*, a replication-deficient viral vector, and
TheraT®*, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration to augment and refresh immune
responses. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other immuno-therapy approaches.
HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in
vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
Cytomegalovirus vaccine candidate is currently in a Phase 2
clinical trial in patients awaiting kidney transplantation from
living Cytomegalovirus-positive donors. To expand its infectious
disease portfolio, HOOKIPA has entered into a collaboration and
licensing agreement with Gilead Sciences, Inc. to jointly research
and develop functional cures for HIV and Hepatitis B
infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The TheraT®
based lead oncology product candidates, HB-201 and HB-202, are in
development for the treatment of Human Papilloma Virus16-positive
cancers. The Phase 1/2 clinical trial for HB-201 was initiated in
December 2019. The HB-202 IND submission is intended for the first
half of 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
*Registered in Europe; Pending in the US.
For further information, please contact:
Media |
Investors |
Nina
Waibel |
Matt
Beck |
Senior
Director - Communications |
Executive
Director - Investor Relations |
Nina.Waibel@HookipaPharma.com |
Matthew.Beck@HookipaPharma.com |
|
|
Media enquiries |
|
Ashley
Tapp |
|
Instinctif
Partners |
|
Hookipa@Instinctif.com |
|
+44 (0)20
7457 2020 |
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024